Cancer Institute A national cancer institute
designated cancer center

Ronald Levy, MD

Publication Details

  • T cell antigen receptor vaccines for active therapy of T cell malignancies Reddy, S. A., Okada, C., Wong, C., Bahler, D., Levy, R. NEW YORK ACAD SCIENCES. 2001: 97-105

    Abstract:

    T cell lymphoproliferative disorders continue to be serious management problems, and so alternative therapeutic modalities are continuously being explored. One such strategy involves immunotherapy using the T cell receptor (TCR) as a target. Specifically we are attempting to develop a T cell receptor idiotype (TCR-Id) vaccine because the TCR-Id can serve as a tumor-specific antigen. In this article we will briefly review the rationale for TCR-Id vaccines, the preclinical models as developed in our laboratory, and a discussion of our current plans for a vaccine trial in mycosis fungoides.

    View details for Web of Science ID 000172619000010

    View details for PubMedID 11594586

Stanford Medicine Resources:

Footer Links: